Genetically engineered mouse models of PI3K signaling in breast cancer

Molecular Oncology

Volumn 7, Issue 2, 2013, Pages 146-164

  Klarenbeek, Sjoerd ^a   van Miltenburg, Martine H ^a   Jonkers, Jos ^a  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

Author keywords

Breast cancer; GEMM ESCs; Mouse models; PI3K signaling; Resistance

Indexed keywords

1 (1 CYANO 1 METHYLETHYL) 3 METHYL 8 (3 QUINOLINYL)IMIDAZO[4,5 C]QUINOLIN 2(1H,3H) ONE; 8 [4 (1 AMINOCYCLOBUTYL)PHENYL] 9 PHENYL 1,2,4 TRIAZOLO[3,4 F][1,6]NAPHTHYRIDIN 3(2H) ONE; AROMATASE INHIBITOR; AZD 5363; AZD 8055; BUPARLISIB; CYTOKERATIN 14; DOXYCYCLINE; EVEROLIMUS; EXEMESTANE; FULVESTRANT; GDC 0032; GDC 0068; GDC 0980; GROWTH FACTOR RECEPTOR; KU 0063794; LETROZOLE; NAVELBINE; NVP BYL 719; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PICTILISIB; TAMOXIFEN; TEMSIROLIMUS; TRASTUZUMAB; UNCLASSIFIED DRUG;

ADENOSQUAMOUS CARCINOMA; ANEMIA; ANOREXIA; ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER GENETICS; CANCER HORMONE THERAPY; CANCER MODEL; CANCER RESISTANCE; CARCINOGENESIS; CELL COUNT; CELL CYCLE PROGRESSION; CELL DIVISION; CELL FUNCTION; CELL SURVIVAL; DIARRHEA; DNA MODIFICATION; DRUG EFFICACY; DRUG SAFETY; EXON; FATIGUE; G2 PHASE CELL CYCLE CHECKPOINT; GENE DELETION; GENE EXPRESSION; GENETIC ENGINEERING; GENOMIC INSTABILITY; HUMAN; HYPERGLYCEMIA; MESENCHYMAL STEM CELL; MYRISTYLATION; NEGATIVE FEEDBACK; NONHUMAN; PHARMACOLOGICAL BLOCKING; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PNEUMONIA; POINT MUTATION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROMOTER REGION; PROTEIN DEPLETION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; REVIEW; SIGNAL TRANSDUCTION; STOMATITIS; TREATMENT RESPONSE;

EID: 84875812144     PISSN: 15747891     EISSN: 18780261     Source Type: Journal    
DOI: 10.1016/j.molonc.2013.02.003     Document Type: Review

References (151)

1. Ackler S., Ahmad S., Tobias C., Johnson M.D., Glazer R.I. Delayed mammary gland involution in MMTV-AKT1 transgenic mice. Oncogene 2002, 21:198-206.
2. Adams J.R., Xu K., Liu J.C., Agamez N.M.R., Loch A.J., Wong R.G., Wang W., Wright K.L., Lane T.F., Zacksenhaus E., Egan S.E. Cooperation between Pik3ca and p53 mutations in mouse mammary tumor formation. Cancer Res. 2011, 71:2706-2717.
3. Alimonti A., Carracedo A., Clohessy J.G., Trotman L.C., Nardella C., Egia A., Salmena L., Sampieri K., Haveman W.J., Brogi E., Richardson A.L., Zhang J., Pandolfi P.P. Subtle variations in Pten dose determine cancer susceptibility. Nat. Genet. 2010, 42:454-458.
4. Andre F., Campone M., O'Regan R., Manlius C., Massacesi C., Sahmoud T., Mukhopadhyay P., Soria J.-C., Naughton M., Hurvitz S.A. Phase I study of everolimus plus weekly paclitaxel and trastuzumab in patients with metastatic breast cancer pretreated with trastuzumab. J. Clin. Oncol. 2010, 28:5110-5115.
5. Bachelot T., Bourgier C., Cropet C., Guastalla J.-P., Ferrero J.-M., Leger-Falandry C., Soulie P., Eymard J.-C., Debled M., Spaeth D., Legouffe E., Delozier T., El Kouri C., Chidiac J. TAMRAD: a GINECO randomized phase II trial of everolimus in combination with tamoxifen versus tamoxifen alone in patients (pts) with hormone-receptor positive, HER2 negative metastatic breast cancer (MBC) with prior exposure to aromatase inhibitors (AI). Cancer Res. 2011, 70. Abstract S1-6.
6. Bachelot T., Bourgier C., Cropet C., Ray-Coquard I., Ferrero J.-M., Freyer G., Abadie-Lacourtoisie S., Eymard J.-C., Debled M., Spaëth D., Legouffe E., Allouache D., El Kouri C., Pujade-Lauraine E. Randomized phase II trial of everolimus in combination with tamoxifen in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer with prior exposure to aromatase inhibitors: a GINECO study. J. Clin. Oncol. 2012, 30:2718-2724.
7. Barbareschi M., Buttitta F., Felicioni L., Cotrupi S., Barassi F., Del Grammastro M., Ferro A., Dalla Palma P., Galligioni E., Marchetti A. Different prognostic roles of mutations in the helical and kinase domains of the PIK3CA gene in breast carcinomas. Clin. Cancer Res. 2007, 13:6064-6069.
8. Baselga J., Campone M., Piccart M., Burris H.A., Rugo H.S., Sahmoud T., Noguchi S., Gnant M., Pritchard K.I., Lebrun F., Beck J.T., Ito Y., Yardley D., Deleu I., Perez A., Bachelot T., Vittori L., Xu Z., Mukhopadhyay P., Lebwohl D., Hortobagyi G.N. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N. Engl. J. Med. 2012, 366:520-529.
9. Baselga J., Semiglazov V., Van Dam P., Manikhas A., Bellet M., Mayordomo J., Campone M., Kubista E., Greil R., Bianchi G., Steinseifer J., Molloy B., Tokaji E., Gardner H., Phillips P., Stumm M., Lane H.A., Dixon J.M., Jonat W., Rugo H.S. Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer. J. Clin. Oncol. 2009, 27:2630-2637.
10. Beard C., Hochedlinger K., Plath K., Wutz A., Jaenisch R. Efficient method to generate single-copy transgenic mice by site-specific integration in embryonic stem cells. Genesis 2006, 44:23-28.
11. Beelen K., Zwart W., Linn S.C. Can predictive biomarkers in breast cancer guide adjuvant endocrine therapy?. Nat. Rev. Clin. Oncol. 2012, 9:529-541.
12. Berenjeno I.M., Guillermet-Guibert J., Pearce W., Gray A., Fleming S., Vanhaesebroeck B. Both p110α and p110β isoforms of PI3K can modulate the impact of loss-of-function of the PTEN tumour suppressor. Biochem. J. 2012, 442:151-159.
13. Berger A.H., Knudson A.G., Pandolfi P.P. A continuum model for tumour suppression. Nature 2011, 476:163-169.
14. Berns K., Horlings H.M., Hennessy B.T., Madiredjo M., Hijmans E.M., Beelen K., Linn S.C., Gonzalez-Angulo A.M., Stemke-Hale K., Hauptmann M., Beijersbergen R.L., Mills G.B., Van de Vijver M.J., Bernards R. A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. Cancer Cell 2007, 12:395-402.
15. Beuvink I., O'Reilly T., Zumstein S., Zilbermann F., Sedrani R., Kozma S., Thomas G., Lane H.A. Antitumor activity of RAD001, an orally active rapamycin derivative. Proc. Am. Assoc. Cancer Res. 2001, 42:366.
16. Blake J.F., Xu R., Bencsik J.R., Xiao D., Kallan N.C., Schlachter S., Mitchell I.S., Spencer K.L., Banka A.L., Wallace E.M., Gloor S.L., Martinson M., Woessner R.D., Vigers G.P., Brandhuber B.J., Liang J., Safina B.S., Li J., Zhang B., Chabot C., Do S., Lee L., Oeh J., Sampath D., Lee B.B., Lin K., Liederer B.M., Skelton N.J. Discovery and preclinical pharmacology of a selective ATP-competitive Akt inhibitor (GDC-0068) for the treatment of human tumors. J. Med. Chem. 2012, 55:8110-8127.
17. Blanco-Aparicio C., Pérez-Gallego L., Pequeño B., Leal J.F.M., Renner O., Carnero A. Mice expressing myrAKT1 in the mammary gland develop carcinogen-induced ER-positive mammary tumors that mimic human breast cancer. Carcinogenesis 2006, 28:584-594.
18. Blasco R.B., Francoz S., Santamaría D., Cañamero M., Dubus P., Charron J., Baccarini M., Barbacid M. c-Raf, but not B-Raf, is essential for development of K-Ras oncogene-driven non-small cell lung carcinoma. Cancer Cell 2011, 19:652-663.
19. Boyault S., Drouet Y., Navarro C., Bachelot T., Lasset C., Treilleux I., Tabone E., Puisieux A., Wang Q. Mutational characterization of individual breast tumors: TP53 and PI3K pathway genes are frequently and distinctively mutated in different subtypes. Breast Cancer Res. Treat. 2012, 132:29-39.
20. Campbell I.G., Russell S.E., Choong D.Y.H., Montgomery K.G., Ciavarella M.L., Hooi C.S.F., Cristiano B.E., Pearson R.B., Phillips W.A. Mutation of the PIK3CA gene in ovarian and breast cancer. Cancer Res. 2004, 64:7678-7681.
21. Carpten J.D., Faber A.L., Horn C., Donoho G.P., Briggs S.L., Robbins C.M., Hostetter G., Boguslawski S., Moses T.Y., Savage S., Uhlik M., Lin A., Du J., Qian Y.-W., Zeckner D.J., Tucker-Kellogg G., Touchman J., Patel K., Mousses S., Bittner M., Schevitz R., Lai M.-H.T., Blanchard K.L., Thomas J.E. A transforming mutation in the pleckstrin homology domain of AKT1 in cancer. Nature 2007, 448:439-444.
22. Carracedo A., Ma L., Teruya-Feldstein J., Rojo F., Salmena L., Alimonti A., Egia A., Sasaki A.T., Thomas G., Kozma S.C., Papa A., Nardella C., Cantley L.C., Baselga J., Pandolfi P.P. Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer. J. Clin. Invest. 2008, 118:3065-3074.
23. Chakrabarty A., Sánchez V., Kuba M.G., Rinehart C., Arteaga C.L. Feedback upregulation of HER3 (ErbB3) expression and activity attenuates antitumor effect of PI3K inhibitors. Proc. Natl. Acad. Sci. U. S. A. 2012, 109:2718-2723.
24. Chandarlapaty S., Sawai A., Scaltriti M., Rodrik-Outmezguine V., Grbovic-Huezo O., Serra V., Majumder P.K., Baselga J., Rosen N. AKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activity. Cancer Cell 2011, 19:58-71.
25. Chang H.W., Aoki M., Fruman D., Auger K.R., Bellacosa A., Tsichlis P.N., Cantley L.C., Roberts T.M., Vogt P.K. Transformation of chicken cells by the gene encoding the catalytic subunit of PI 3-kinase. Science 1997, 276:1848-1850.
26. Chen Z., Cheng K., Walton Z., Wang Y., Ebi H., Shimamura T., Liu Y., Tupper T., Ouyang J., Li J., Gao P., Woo M.S., Xu C., Yanagita M., Altabef A., Wang S., Lee C., Nakada Y., Peña C.G., Sun Y., Franchetti Y., Yao C., Saur A., Cameron M.D., Nishino M., Hayes D.N., Wilkerson M.D., Roberts P.J., Lee C.B., Bardeesy N., Butaney M., Chirieac L.R., Costa D.B., Jackman D., Sharpless N.E., Castrillon D.H., Demetri G.D., Jänne P.A., Pandolfi P.P., Cantley L.C., Kung A.L., Engelman J.A., Wong K.-K. A murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic response. Nature 2012, 483:613-617.
27. Chiu C.W., Nozawa H., Hanahan D. Survival benefit with proapoptotic molecular and pathologic responses from dual targeting of mammalian target of rapamycin and epidermal growth factor receptor in a preclinical model of pancreatic neuroendocrine carcinogenesis. J. Clin. Oncol. 2010, 28:4425-4433.
28. Chresta C.M., Davies B.R., Hickson I., Harding T., Cosulich S., Critchlow S.E., Vincent J.P., Ellston R., Jones D., Sini P., James D., Howard Z., Dudley P., Hughes G., Smith L., Maguire S., Hummersone M., Malagu K., Menear K., Jenkins R., Jacobsen M., Smith G.C.M., Guichard S., Pass M. AZD8055 is a potent, selective, and orally bioavailable ATP-competitive mammalian target of rapamycin kinase inhibitor with in vitro and in vivo antitumor activity. Cancer Res. 2010, 70:288-298.
29. Ciampricotti M., Hau C.-S., Doornebal C.W., Jonkers J., Visser K.E.de Chemotherapy response of spontaneous mammary tumors is independent of the adaptive immune system. Nat. Med. 2012, 18:344-346.
30. Copeland N.G., Jenkins N.A. Harnessing transposons for cancer gene discovery. Nat. Rev. Cancer 2010, 10:696-706.
31. Courtney K.D., Corcoran R.B., Engelman J.A. The PI3K pathway as drug target in human cancer. J. Clin. Oncol. 2010, 28:1075-1083.
32. Damen J.E., Liu L., Rosten P., Humphries R.K., Jefferson A.B., Majerus P.W., Krystal G. The 145-kDa protein induced to associate with Shc by multiple cytokines is an inositol tetraphosphate and phosphatidylinositol 3,4,5-triphosphate 5-phosphatase. Proc. Natl. Acad. Sci. U. S. A. 1996, 93:1689-1693.
33. Davies B.R., Greenwood H., Dudley P., Crafter C., Yu D.-H., Zhang J., Li J., Gao B., Ji Q., Maynard J., Ricketts S.-A., Cross D., Cosulich S., Chresta C.C., Page K., Yates J., Lane C., Watson R., Luke R., Ogilvie D., Pass M. Preclinical pharmacology of AZD5363, an inhibitor of AKT: pharmacodynamics, antitumor activity, and correlation of monotherapy activity with genetic background. Mol. Cancer Ther. 2012, 11:873-887.
34. DeNardo D.G., Brennan D.J., Rexhepaj E., Ruffell B., Shiao S.L., Madden S.F., Gallagher W.M., Wadhwani N., Keil S.D., Junaid S.A., Rugo H.S., Hwang E.S., Jirström K., West B.L., Coussens L.M. Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy. Cancer Discov. 2011, 1:54-67.
35. DeRose Y.S., Wang G., Lin Y.-C., Bernard P.S., Buys S.S., Ebbert M.T.W., Factor R., Matsen C., Milash B.A., Nelson E., Neumayer L., Randall R.L., Stijleman I.J., Welm B.E., Welm A.L. Tumor grafts derived from women with breast cancer authentically reflect tumor pathology, growth, metastasis and disease outcomes. Nat. Med. 2011, 17:1514-1520.
36. Dillon R.L., Marcotte R., Hennessy B.T., Woodgett J.R., Mills G.B., Muller W.J. Akt1 and Akt2 play distinct roles in the initiation and metastatic phases of mammary tumor progression. Cancer Res. 2009, 69:5057-5064.
37. Dow L.E., Lowe S.W. Life in the fast lane: mammalian disease models in the genomics era. Cell 2012, 148:1099-1109.
38. Dudkin L., Dilling M.B., Cheshire P.J., Harwood F.C., Hollingshead M., Arbuck S.G., Travis R., Sausville E.A., Houghton P.J. Biochemical correlates of mTOR inhibition by the rapamycin ester CCI-779 and tumor growth inhibition. Clin. Cancer Res. 2001, 7:1758-1764.
39. Dumont A.G., Dumont S.N., Trent J.C. The favorable impact of PIK3CA mutations on survival: an analysis of 2587 patients with breast cancer. Chin. J. Cancer 2012, 31:327-334.
40. Dunlap J., Le C., Shukla A., Patterson J., Presnell A., Heinrich M.C., Corless C.L., Troxell M.L. Phosphatidylinositol-3-kinase and AKT1 mutations occur early in breast carcinoma. Breast Cancer Res. Treat. 2010, 120:409-418.
41. DuPage M., Mazumdar C., Schmidt L.M., Cheung A.F., Jacks T. Expression of tumour-specific antigens underlies cancer immunoediting. Nature 2012, 482:405-409.
42. Dupont J., Renou J.P., Shani M., Hennighausen L., LeRoith D. PTEN overexpression suppresses proliferation and differentiation and enhances apoptosis of the mouse mammary epithelium. J. Clin. Invest. 2002, 110:815-825.
43. Dupont Jensen J., Laenkholm A.-V., Knoop A., Ewertz M., Bandaru R., Liu W., Hackl W., Barrett J.C., Gardner H. PIK3CA mutations may be discordant between primary and corresponding metastatic disease in breast cancer. Clin. Cancer Res. 2011, 17:667-677.
44. Ellis M.J., Ding L., Shen D., Luo J., Suman V.J., et al. Whole-genome analysis informs breast cancer response to aromatase inhibition. Nature 2012, 486:353-360.
45. Engelman J.A., Chen L., Tan X., Crosby K., Guimaraes A.R., Upadhyay R., Maira M., McNamara K., Perera S.A., Song Y., Chirieac L.R., Kaur R., Lightbown A., Simendinger J., Li T., Padera R.F., García-Echeverría C., Weissleder R., Mahmood U., Cantley L.C., Wong K.-K. Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers. Nat. Med. 2008, 14:1351-1356.
46. Esteva F.J., Guo H., Zhang S., Santa-Maria C., Stone S., Lanchbury J.S., Sahin A.A., Hortobagyi G.N., Yu D. PTEN, PIK3CA, p-AKT, and p-p70S6K status: association with trastuzumab response and survival in patients with HER2-positive metastatic breast cancer. Am. J. Pathol. 2010, 177:1647-1656.
47. Faber A.C., Li D., Song Y., Liang M.-C., Yeap B.Y., Bronson R.T., Lifshits E., Chen Z., Maira S.-M., García-Echeverría C., Wong K.-K., Engelman J.A. Differential induction of apoptosis in HER2 and EGFR addicted cancers following PI3K inhibition. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:19503-19508.
48. Fedele C.G., Ooms L.M., Ho M., Vieusseux J., O'Toole S.A., Millar E.K., Lopez-Knowles E., Sriratana A., Gurung R., Baglietto L., Giles G.G., Bailey C.G., Rasko J.E.J., Shields B.J., Price J.T., Majerus P.W., Sutherland R.L., Tiganis T., McLean C.A., Mitchell C.A. Inositol polyphosphate 4-phosphatase II regulates PI3K/Akt signaling and is lost in human basal-like breast cancers. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:22231-22236.
49. Feldman M.E., Apsel B., Uotila A., Loewith R., Knight Z.A., Ruggero D., Shokat K.M. Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2. PLoS Biol. 2009, 7:e38.
50. Ferlay J., Shin H.-R., Bray F., Forman D., Mathers C., Parkin D.M. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int. J. Cancer 2010, 127:2893-2917.
51. Folkes Tabladi K., Alderton W.K., Alix S., Baker S.J., Box G., Chuckowree I.S., Clarke P.A., Depledge P., Eccles S.A., Friedman L.S., Hayes A., Hancox T.C., Kugendradas A., Lensun L., Moore P., Olivero A.G., Pang J., Patel S., Pergl-Wilson G.H., Raynaud F.I., Robson A., Saghir N., Salphati L., Sohal S., Ultsch M.H., Valenti M., Wallweber H.J., Wan N.C., Wiesmann C., Workman P., Zhyvoloup A., Zvelebil M.J., Shuttleworth S.J. The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-t hieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer. J. Med. Chem. 2008, 51:5522-5532.
52. Frese K.K., Tuveson D.A. Maximizing mouse cancer models. Nat. Rev. Cancer 2007, 7:645-658.
53. Friedman L., Ross L.B., Wallin J., Guan J., Prior W.W., Wu E., Nannini M., Sampath D. Selective PI3K and dual PI3K/mTOR inhibitors enhance the efficacy of endocrine therapies in breast cancer models. Cancer Res. 2012, 72(Suppl. 24). Abstract P5-19-02.
54. Fritsch C.M., Schnell C., Chatenay-Rivauday C., Guthy D.A., De Pover A., Wartmann M., Brachmann S., Maira S.M., Huang A., Quadt C., Hofmann F., Caravatti G. NVP-BYL719, a novel PI3Kalpha selective inhibitor with all the characteristics required for clinical development as an anti-cancer agent. Cancer Res. 2012, 72(Suppl. 8). Abstract 3748.
55. Gallardo A., Lerma E., Escuin D., Tibau A., Muñoz J., Ojeda B., Barnadas A., Adrover E., Sánchez-Tejada L., Giner D., Ortiz-Martínez F., Peiró G. Increased signalling of EGFR and IGF1R, and deregulation of PTEN/PI3K/Akt pathway are related with trastuzumab resistance in HER2 breast carcinomas. Br. J. Cancer 2012, 106:1367-1373.
56. Gao D., Inuzuka H., Tseng A., Chin R.Y., Toker A., Wei W. Phosphorylation by Akt1 promotes Skp2 cytoplasmic localization and impairs APC/Cdh1-mediated Skp2 destruction. Nat. Cell. Biol. 2009, 11:397-408.
57. García-Martínez J.M., Moran J., Clarke R.G., Gray A., Cosulich S.C., Chresta C.M., Alessi D.R. Ku-0063794 is a specific inhibitor of the mammalian target of rapamycin (mTOR). Biochem. J. 2009, 421:29-42.
58. Gewinner C., Wang Z.C., Richardson A., Teruya-Feldstein J., Etemadmoghadam D., Bowtell D., Barretina J., Lin W.M., Rameh L., Salmena L., Pandolfi P.P., Cantley L.C. Evidence that inositol polyphosphate 4-phosphatase type II is a tumor suppressor that inhibits PI3K signaling. Cancer Cell 2009, 16:115-125.
59. Gonzalez-Angulo A.M., Ferrer-Lozano J., Stemke-Hale K., Sahin A., Liu S., Barrera J.A., Burgues O., Lluch A.M., Chen H., Hortobagyi G.N., Mills G.B., Meric-Bernstam F. PI3K pathway mutations and PTEN levels in primary and metastatic breast cancer. Mol. Cancer Ther. 2011, 10:1093-1101.
60. Hirai H., Sootome H., Nakatsuru Y., Miyama K., Taguchi S., Tsujioka K., Ueno Y., Hatch H., Majumder P.K., Pan B.-S., Kotani H. MK-2206, an allosteric Akt inhibitor, enhances antitumor efficacy by standard chemotherapeutic agents or molecular targeted drugs in vitro and in vivo. Mol. Cancer Ther. 2010, 9:1956-1967.
61. Huijbers I.J., Krimpenfort P., Berns A., Jonkers J. Rapid validation of cancer genes in chimeras derived from established genetically engineered mouse models. Bioessays 2011, 33:701-710.
62. Jerusalem G., Fasolo A., Dieras V., Cardoso F., Bergh J., Vittori L., Zhang Y., Massacesi C., Sahmoud T., Gianni L. Phase I trial of oral mTOR inhibitor everolimus in combination with trastuzumab and vinorelbine in pre-treated patients with HER2-overexpressing metastatic breast cancer. Breast Cancer Res. Treat. 2011, 125:447-455.
63. Jonkers J., Berns A. Conditional mouse models of sporadic cancer. Nat. Rev. Cancer 2002, 2:251-265.
64. Jonkers J., Meuwissen R., Van der Gulden H., Peterse H., Van der Valk M., Berns A. Synergistic tumor suppressor activity of BRCA2 and p53 in a conditional mouse model for breast cancer. Nat. Genet. 2001, 29:418-425.
65. Juvekar A., Burga L.N., Hu H., Lunsford E.P., Ibrahim Y.H., Balmañà J., Rajendran A., Papa A., Spencer K., Lyssiotis C.A., Nardella C., Pandolfi P.P., Baselga J., Scully R., Asara J.M., Cantley L.C., Wulf G.M. Combining a PI3K inhibitor with a PARP inhibitor provides an effective therapy for BRCA1-related breast cancer. Cancer Discov. 2012, 2:1048-1063.
66. Keng V.W., Villanueva A., Chiang D.Y., Dupuy A.J., Ryan B.J., Matise I., Silverstein K.A.T., Sarver A., Starr T.K., Akagi K., Tessarollo L., Collier L.S., Powers S., Lowe S.W., Jenkins N.A., Copeland N.G., Llovet J.M., Largaespada D.A. A conditional transposon-based insertional mutagenesis screen for genes associated with mouse hepatocellular carcinoma. Nat. Biotechnol. 2009, 27:264-274.
67. Knudson A.G. Mutation and cancer: statistical study of retinoblastoma. Proc. Natl. Acad. Sci. U. S. A. 1971, 68:820-823.
68. Kool J., Berns A. High-throughput insertional mutagenesis screens in mice to identify oncogenic networks. Nat. Rev. Cancer 2009, 9:389-399.
69. LaRocca J., Pietruska J., Hixon M. Akt1 is essential for postnatal mammary gland development, function, and the expression of Btn1a1. PLoS One 2011, 6:e24432.
70. Lauchle J.O., Kim D., Le D.T., Akagi K., Crone M., Krisman K., Warner K., Bonifas J.M., Li Q., Coakley K.M., Diaz-Flores E., Gorman M., Przybranowski S., Tran M., Kogan S.C., Roose J.P., Copeland N.G., Jenkins N.A., Parada L., Wolff L., Sebolt-Leopold J., Shannon K. Response and resistance to MEK inhibition in leukaemias initiated by hyperactive Ras. Nature 2009, 461:411-414.
71. Lewandoski M. Conditional control of gene expression in the mouse. Nat. Rev. Genet. 2001, 2:743-755.
72. Li G., Robinson G.W., Lesche R., Martinez-Diaz H., Jiang Z., Rozengurt N., Wagner K.-U., Wu D.-C., Lane T.F., Liu X., Hennighausen L., Wu H. Conditional loss of PTEN leads to precocious development and neoplasia in the mammary gland. Development 2002, 129:4159-4170.
73. Li J., Yen C., Liaw D., Podsypanina K., Bose S., Wang S.I., Puc J., Miliaresis C., Rodgers L., McCombie R., Bigner S.H., Giovanella B.C., Ittmann M., Tycko B., Hibshoosh H., Wigler M.H., Parsons R. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 1997, 275:1943-1947.
74. Li Y., Podsypanina K., Liu X., Crane A., Tan L.K., Parsons R., Varmus H.E. Deficiency of Pten accelerates mammary oncogenesis in MMTV-Wnt-1 transgenic mice. BMC Mol. Biol. 2001, 2:2.
75. Lin J., Sampath D., Nannini M.A., Lee B.B., Degtyarev M., Oeh J., Savage H., Guan Z., Hong R., Kassees R., Lee L.B., Risom T., Gross S.D., Liederer B., Koeppen H., Skelton N., Wallin J.J., Belvin M., Punnoose E.A., Friedman L.S., Lin K. Targeting activated Akt with GDC-0068, a novel selective Akt inhibitor that is efficacious in multiple tumor models. Clin. Cancer Res. 2013, ([Epub ahead of print]).
76. Liu P., Cheng H., Santiago S., Raeder M., Zhang F., Isabella A., Yang J., Semaan D.J., Chen C., Fox E.A., Gray N.S., Monahan J., Schlegel R., Beroukhim R., Mills G.B., Zhao J.J. Oncogenic PIK3CA-driven mammary tumors frequently recur via PI3K pathway-dependent and PI3K pathway-independent mechanisms. Nat. Med. 2011, 17:1116-1120.
77. Loi S., Haibe-Kains B., Majjaj S., Lallemand F., Durbecq V., Larsimont D., Gonzalez-Angulo A.M., Pusztai L., Symmans W.F., Bardelli A., Ellis P., Tutt A.N.J., Gillett C.E., Hennessy B.T., Mills G.B., Phillips W.A., Piccart M.J., Speed T.P., McArthur G.A., Sotiriou C. PIK3CA mutations associated with gene signature of low mTORC1 signaling and better outcomes in estrogen receptor-positive breast cancer. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:10208-10213.
78. Maira S.-M., Pecchi S., Huang A., Burger M., Knapp M., Sterker D., Schnell C., Guthy D., Nagel T., Wiesmann M., Brachmann S., Fritsch C., Dorsch M., Chène P., Shoemaker K., De Pover A., Menezes D., Martiny-Baron G., Fabbro D., Wilson C.J., Schlegel R., Hofmann F., García-Echeverría C., Sellers W.R., Voliva C.F. Identification and characterization of NVP-BKM120, an orally available pan-class I PI3-kinase inhibitor. Mol. Cancer Ther. 2012, 11:317-328.
79. Maira S.-M., Stauffer F., Brueggen J., Furet P., Schnell C., Fritsch C., Brachmann S., Chène P., De Pover A., Schoemaker K., Fabbro D., Gabriel D., Simonen M., Murphy L., Finan P., Sellers W., García-Echeverría C. Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity. Mol. Cancer Ther. 2008, 7:1851-1863.
80. Manning B.D., Cantley L.C. AKT/PKB signaling: navigating downstream. Cell 2007, 129:1261-1274.
81. March H.N., Rust A.G., Wright N.A., Ten Hoeve J., De Ridder J., Eldridge M., Van der Weyden L., Berns A., Gadiot J., Uren A., Kemp R., Arends M.J., Wessels L.F.A., Winton D.J., Adams D.J. Insertional mutagenesis identifies multiple networks of cooperating genes driving intestinal tumorigenesis. Nat. Genet. 2011, 43:1202-1209.
82. Maroulakou I.G., Oemler W., Naber S.P., Klebba I., Kuperwasser C., Tsichlis P.N. Distinct roles of the three Akt isoforms in lactogenic differentiation and involution. J. Cell. Physiol. 2008, 217:468-477.
83. Maroulakou I.G., Oemler W., Naber S.P., Tsichlis P.N. Akt1 ablation inhibits, whereas Akt2 ablation accelerates, the development of mammary adenocarcinomas in mouse mammary tumor virus (MMTV)-ErbB2/neu and MMTV-polyoma middle T transgenic mice. Cancer Res. 2007, 67:167-177.
84. Martins F.C., De S., Almendro V., Gönen M., Park S.Y., Blum J.L., Herlihy W., Ethington G., Schnitt S.J., Tung N., Garber J.E., Fetten K., Michor F., Polyak K. Evolutionary pathways in BRCA1-associated breast tumors. Cancer Discov. 2012, 2:503-511.
85. Masui S., Shimosato D., Toyooka Y., Yagi R., Takahashi K., Niwa H. An efficient system to establish multiple embryonic stem cell lines carrying an inducible expression unit. Nucleic Acids Res. 2005, 33:e43.
86. Mendes-Pereira A.M., Martin S.A., Brough R., McCarthy A., Taylor J.R., Kim J.-S., Waldman T., Lord C.J., Ashworth A. Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors. EMBO Mol. Med. 2009, 1:315-322.
87. Meyer D.S., Brinkhaus H., Müller U., Müller M., Cardiff R.D., Bentires-Alj M. Luminal expression of PIK3CA mutant H1047R in the mammary gland induces heterogeneous tumors. Cancer Res. 2011, 71:4344-4351.
88. Morrow P.K., Wulf G.M., Ensor J., Booser D.J., Moore J.A., Flores P.R., Xiong Y., Zhang S., Krop I.E., Winer E.P., Kindelberger D.W., Coviello J., Sahin A.A., Nuñez R., Hortobagyi G.N., Yu D., Esteva F.J. Phase I/II study of trastuzumab in combination with everolimus (RAD001) in patients with HER2-overexpressing metastatic breast cancer who progressed on trastuzumab-based therapy. J. Clin. Oncol. 2011, 29:3126-3132.
89. Muranen T., Selfors L.M., Worster D.T., Iwanicki M.P., Song L., Morales F.C., Gao S., Mills G.B., Brugge J.S. Inhibition of PI3K/mTOR leads to adaptive resistance in matrix-attached cancer cells. Cancer Cell 2012, 21:227-239.
90. Nagata Y., Lan K.-H., Zhou X., Tan M., Esteva F.J., Sahin A.A., Klos K.S., Li P., Monia B.P., Nguyen N.T., Hortobagyi G.N., Hung M.-C., Yu D. PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell 2004, 6:117-127.
91. O'Brien N.A., Browne B.C., Chow L., Wang Y., Ginther C., Arboleda J., Duffy M.J., Crown J., O'Donovan N., Slamon D.J. Activated phosphoinositide 3-kinase/AKT signaling confers resistance to trastuzumab but not lapatinib. Mol. Cancer Ther. 2010, 9:1489-1502.
92. O'Reilly K.E., Rojo F., She Q.-B., Solit D., Mills G.B., Smith D., Lane H., Hofmann F., Hicklin D.J., Ludwig D.L., Baselga J., Rosen N. mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res. 2006, 66:1500-1508.
93. Pang H., Flinn R., Patsialou A., Wyckoff J., Roussos E.T., Wu H., Pozzuto M., Goswami S., Condeelis J.S., Bresnick A.R., Segall J.E., Backer J.M. Differential enhancement of breast cancer cell motility and metastasis by helical and kinase domain mutations of class IA phosphoinositide 3-kinase. Cancer Res. 2009, 69:8868-8876.
94. Panigrahi A.R., Pinder S.E., Chan S.Y., Paish E.C., Robertson J.F.R., Ellis I.O. The role of PTEN and its signalling pathways, including AKT, in breast cancer; an assessment of relationships with other prognostic factors and with outcome. J. Pathol. 2004, 204:93-100.
95. Pérez-Tenorio G., Alkhori L., Olsson B., Waltersson M.A., Nordenskjöld B., Rutqvist L.E., Skoog L., Stål O. PIK3CA mutations and PTEN loss correlate with similar prognostic factors and are not mutually exclusive in breast cancer. Clin. Cancer Res. 2007, 13:3577-3584.
96. Pittius C.W., Hennighausen L., Lee E., Westphal H., Nicols E., Vitale J., Gordon K. A milk protein gene promoter directs the expression of human tissue plasminogen activator cDNA to the mammary gland in transgenic mice. Proc. Natl. Acad. Sci. U. S. A. 1988, 85:5874-5878.
97. Podsypanina K., Ellenson L.H., Nemes A., Gu J., Tamura M., Yamada K.M., Cordon-Cardo C., Catoretti G., Fisher P.E., Parsons R. Mutation of Pten/Mmac1 in mice causes neoplasia in multiple organ systems. Proc. Natl. Acad. Sci. U. S. A. 1999, 96:1563-1568.
98. Premsrirut P.K., Dow L.E., Kim S.Y., Camiolo M., Malone C.D., Miething C., Scuoppo C., Zuber J., Dickins R.A., Kogan S.C., Shroyer K.R., Sordella R., Hannon G.J., Lowe S.W. A rapid and scalable system for studying gene function in mice using conditional RNA interference. Cell 2011, 145:145-158.
99. Puc J., Keniry M., Li H.S., Pandita T.K., Choudhury A.D., Memeo L., Mansukhani M., Murty V.V.V.S., Gaciong Z., Meek S.E.M., Piwnica-Worms H., Hibshoosh H., Parsons R. Lack of PTEN sequesters CHK1 and initiates genetic instability. Cancer Cell 2005, 7:193-204.
100. Rad R., Rad L., Wang W., Cadinanos J., Vassiliou G., Rice S., Campos L.S., Yusa K., Banerjee R., Li M.A., De la Rosa J., Strong A., Lu D., Ellis P., Conte N., Yang F.T., Liu P., Bradley A. PiggyBac transposon mutagenesis: a tool for cancer gene discovery in mice. Science 2010, 330:1104-1107.
101. Razis E., Bobos M., Kotoula V., Eleftheraki A.G., Kalofonos H.P., Pavlakis K., Papakostas P., Aravantinos G., Rigakos G., Efstratiou I., Petraki K., Bafaloukos D., Kostopoulos I., Pectasides D., Kalogeras K.T., Skarlos D., Fountzilas G. Evaluation of the association of PIK3CA mutations and PTEN loss with efficacy of trastuzumab therapy in metastatic breast cancer. Breast Cancer Res. Treat. 2011, 128:447-456.
102. Roberts P.J., Usary J.E., Darr D.B., Dillon P.M., Pfefferle A.D., Whittle M.C., Duncan J.S., Johnson S.M., Combest A.J., Jin J., Zamboni W.C., Johnson G.L., Perou C.M., Sharpless N.E. Combined PI3K/mTOR and MEK inhibition provides broad antitumor activity in faithful murine cancer models. Clin. Cancer Res. 2012, 18:5290-5303.
103. Rodrik-Outmezguine V.S., Chandarlapaty S., Pagano N.C., Poulikakos P.I., Scaltriti M., Moskatel E., Baselga J., Guichard S., Rosen N. mTOR kinase inhibition causes feedback-dependent biphasic regulation of AKT signaling. Cancer Discov. 2011, 1:248-259.
104. Roper J., Richardson M.P., Wang W.V., Richard L.G., Chen W., Coffee E.M., Sinnamon M.J., Lee L., Chen P.-C., Bronson R.T., Martin E.S., Hung K.E. The dual PI3K/mTOR inhibitor NVP-BEZ235 induces tumor regression in a genetically engineered mouse model of PIK3CA wild-type colorectal cancer. PLoS One 2011, 6:e25132.
105. Rottenberg S., Pajic M., Jonkers J. Studying drug resistance using genetically engineered mouse models for breast cancer. Methods Mol. Biol. 2010, 596:33-45.
106. Saal L.H., Gruvberger-Saal S.K., Persson C., Lövgren K., Jumppanen M., Staaf J., Jönsson G., Pires M.M., Maurer M., Holm K., Koujak S., Subramaniyam S., Vallon-Christersson J., Olsson H., Su T., Memeo L., Ludwig T., Ethier S.P., Krogh M., Szabolcs M., Murty V.V.V.S., Isola J., Hibshoosh H., Parsons R., Borg A. Recurrent gross mutations of the PTEN tumor suppressor gene in breast cancers with deficient DSB repair. Nat. Genet. 2008, 40:102-107.
107. Saal L.H., Holm K., Maurer M., Memeo L., Su T., Wang X., Yu J.S., Malmström P.-O., Mansukhani M., Enoksson J., Hibshoosh H., Borg A., Parsons R. PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma. Cancer Res. 2005, 65:2554-2559.
108. Sadeq V., Isar N., Manoochehr T. Association of sporadic breast cancer with PTEN/MMAC1/TEP1 promoter hypermethylation. Med. Oncol. 2011, 28:420-423.
109. Santarpia L., Qi Y., Stemke-Hale K., Wang B., Young E.J., Booser D.J., Holmes F.A., O'Shaughnessy J., Hellerstedt B., Pippen J., Vidaurre T., Gomez H., Valero V., Hortobagyi G.N., Symmans W.F., Bottai G., Di Leo A., Gonzalez-Angulo A.M., Pusztai L. Mutation profiling identifies numerous rare drug targets and distinct mutation patterns in different clinical subtypes of breast cancers. Breast Cancer Res. Treat. 2012, 134:333-343.
110. Schade B., Rao T., Dourdin N., Lesurf R., Hallett M., Cardiff R.D., Muller W.J. PTEN deficiency in a luminal ErbB-2 mouse model results in dramatic acceleration of mammary tumorigenesis and metastasis. J. Biol. Chem. 2009, 284:19018-19026.
111. Schwertfeger K.L., Richert M.M., Anderson S.M. Mammary gland involution is delayed by activated akt in transgenic mice. Mol. Endocrinol. 2001, 15:867-881.
112. Shah S.P., Roth A., Goya R., Oloumi A., Ha G., et al. The clonal and mutational evolution spectrum of primary triple-negative breast cancers. Nature 2012, 486:395-399.
113. Sharpless N.E., Depinho R.A. The mighty mouse: genetically engineered mouse models in cancer drug development. Nat. Rev. Drug Discov. 2006, 5:741-754.
114. She Q.-B., Halilovic E., Ye Q., Zhen W., Shirasawa S., Sasazuki T., Solit D.B., Rosen N. 4E-BP1 is a key effector of the oncogenic activation of the AKT and ERK signaling pathways that integrates their function in tumors. Cancer Cell 2010, 18:39-51.
115. Shen W.H., Balajee A.S., Wang J., Wu H., Eng C., Pandolfi P.P., Yin Y. Essential role for nuclear PTEN in maintaining chromosomal integrity. Cell 2007, 128:157-170.
116. Shetty P.J., Pasupuleti N., Chava S., Nasaruddin K., Hasan Q. Altered transcription and expression of PTEN in breast tumors: is it regulated by hypermethylation?. Breast Dis. 2011, 33:27-33.
117. Singh M., Lima A., Molina R., Hamilton P., Clermont A.C., Devasthali V., Thompson J.D., Cheng J.H., Bou Reslan H., Ho C.C.K., Cao T.C., Lee C.V., Nannini M.A., Fuh G., Carano R.A.D., Koeppen H., Yu R.X., Forrest W.F., Plowman G.D., Johnson L. Assessing therapeutic responses in Kras mutant cancers using genetically engineered mouse models. Nat. Biotechnol. 2010, 28:585-593.
118. Song M.S., Carracedo A., Salmena L., Song S.J., Egia A., Malumbres M., Pandolfi P.P. Nuclear PTEN regulates the APC-CDH1 tumor-suppressive complex in a phosphatase-independent manner. Cell 2011, 144:187-199.
119. Song M.S., Salmena L., Pandolfi P.P. The functions and regulation of the PTEN tumour suppressor. Nat. Rev. Mol. Cell. Biol. 2012, 13:283-296.
120. Staal S.P. Molecular cloning of the akt oncogene and its human homologues AKT1 and AKT2: amplification of AKT1 in a primary human gastric adenocarcinoma. Proc. Natl. Acad. Sci. U. S. A. 1987, 84:5034-5037.
121. Stambolic V., Suzuki A., De la Pompa J.L., Brothers G.M., Mirtsos C., Sasaki T., Ruland J., Penninger J.M., Siderovski D.P., Mak T.W. Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN. Cell 1998, 95:29-39.
122. Stambolic V., Tsao M.S., Macpherson D., Suzuki A., Chapman W.B., Mak T.W. High incidence of breast and endometrial neoplasia resembling human Cowden syndrome in pten+/- mice. Cancer Res. 2000, 60:3605-3611.
123. Steck P.A., Pershouse M.A., Jasser S.A., Yung W.K., Lin H., Ligon A.H., Langford L.A., Baumgard M.L., Hattier T., Davis T., Frye C., Hu R., Swedlund B., Teng D.H., Tavtigian S.V. Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nat. Genet. 1997, 15:356-362.
124. Stemke-Hale K., Gonzalez-Angulo A.M., Lluch A., Neve R.M., Kuo W.-L., Davies M., Carey M., Hu Z., Guan Y., Sahin A., Symmans W.F., Pusztai L., Nolden L.K., Horlings H., Berns K., Hung M.-C., Van de Vijver M.J., Valero V., Gray J.W., Bernards R., Mills G.B., Hennessy B.T. An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer. Cancer Res. 2008, 68:6084-6091.
125. Stephens P.J., Tarpey P.S., Davies H., Van Loo P., Greenman C., et al. The landscape of cancer genes and mutational processes in breast cancer. Nature 2012, 486:400-404.
126. Stewart T.A., Pattengale P.K., Leder P. Spontaneous mammary adenocarcinomas in transgenic mice that carry and express MTV/myc fusion genes. Cell 1984, 38:627-637.
127. Sutherlin D.P., Bao L., Berry M., Castanedo G., Chuckowree I., Dotson J., Folks A., Friedman L., Goldsmith R., Gunzner J., Heffron T., Lesnick J., Lewis C., Mathieu S., Murray J., Nonomiya J., Pang J., Pegg N., Prior W.W., Rouge L., Salphati L., Sampath D., Tian Q., Tsui V., Wan N.C., Wang S., Wei B., Wiesmann C., Wu P., Zhu B.Y., Olivero A. Discovery of a potent, selective, and orally available class I phosphatidylinositol 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) kinase inhibitor (GDC-0980) for the treatment of cancer. J. Med. Chem. 2011, 54:7579-7587.
128. Suzuki A., De la Pompa J.L., Stambolic V., Elia A.J., Sasaki T., Del Barco Barrantes I., Ho A., Wakeham A., Itie A., Khoo W., Fukumoto M., Mak T.W. High cancer susceptibility and embryonic lethality associated with mutation of the PTEN tumor suppressor gene in mice. Curr. Biol. 1998, 8:1169-1178.
129. Tentler J.J., Tan A.C., Weekes C.D., Jimeno A., Leong S., Pitts T.M., Arcaroli J.J., Messersmith W.A., Eckhardt S.G. Patient-derived tumour xenografts as models for oncology drug development. Nat. Rev. Clin. Oncol. 2012, 9:338-350.
130. The Cancer Genome Atlas Network Comprehensive molecular portraits of human breast tumours. Nature 2012, 490:61-70.
131. Thoreen C.C., Kang S.A., Chang J.W., Liu Q., Zhang J., Gao Y., Reichling L.J., Sim T., Sabatini D.M., Gray N.S. An ATP-competitive mammalian target of rapamycin inhibitor reveals rapamycin-resistant functions of mTORC1. J. Biol. Chem. 2009, 284:8023-8032.
132. Tikoo A., Roh V., Montgomery K.G., Ivetac I., Waring P., Pelzer R., Hare L., Shackleton M., Humbert P., Phillips W.A. Physiological levels of Pik3ca(H1047R) mutation in the mouse mammary gland results in ductal hyperplasia and formation of ERα-positive tumors. PLoS One 2012, 7:e36924.
133. Torbett N.E., Luna-Moran A., Knight Z.A., Houk A., Moasser M., Weiss W., Shokat K.M., Stokoe D. A chemical screen in diverse breast cancer cell lines reveals genetic enhancers and suppressors of sensitivity to PI3K isoform-selective inhibition. Biochem. J. 2008, 415:97-110.
134. Uren A.G., Mikkers H., Kool J., Van der Weyden L., Lund A.H., Wilson C.H., Rance R., Jonkers J., Van Lohuizen M., Berns A., Adams D.J. A high-throughput splinkerette-PCR method for the isolation and sequencing of retroviral insertion sites. Nat. Protoc. 2009, 4:789-798.
135. Utermark T., Rao T., Cheng H., Wang Q., Lee S.H., Wang Z.C., Iglehart J.D., Roberts T.M., Muller W.J., Zhao J.J. The p110α and p110β isoforms of PI3K play divergent roles in mammary gland development and tumorigenesis. Genes Dev. 2012, 26:1573-1586.
136. Vanhaesebroeck B., Guillermet-Guibert J., Graupera M., Bilanges B. The emerging mechanisms of isoform-specific PI3K signalling. Nat. Rev. Mol. Cell. Biol. 2010, 11:329-341.
137. Wall M., Poortinga G., Stanley K.L., Lindemann R.K., Bots M., Chan C.J., Bywater M.J., Kinross K.M., Astle M.V., Waldeck K., Hannan K.M., Shortt J., Smyth M.J., Lowe S.W., Hannan R.D., Pearson R.B., Johnstone R.W., McArthur G.A. The mTORC1 inhibitor everolimus prevents and treats Eμ-myc lymphoma by Restoring oncogene-induced Senescence. Cancer Discov. 2013, 3:82-95.
138. Wallin J.J., Edgar K.A., Guan J., Berry M., Prior W.W., Lee L., Lesnick J.D., Lewis C., Nonomiya J., Pang J., Salphati L., Olivero A.G., Sutherlin D.P., O'Brien C., Spoerke J.M., Patel S., Lensun L., Kassees R., Ross L., Lackner M.R., Sampath D., Belvin M., Friedman L.S. GDC-0980 is a novel class I PI3K/mTOR kinase inhibitor with robust activity in cancer models driven by the PI3K pathway. Mol. Cancer Ther. 2011, 10:2426-2436.
139. Walrath J.C., Hawes J.J., Van Dyke T., Reilly K.M. Genetically engineered mouse models in cancer research. Adv. Cancer Res. 2010, 106:113-164.
140. Webster J., Wallace R.M., Clark A.J., Whitelaw C.B. Tissue-specific, temporally regulated expression mediated by the proximal ovine beta-lactoglobulin promoter in transgenic mice. Cell. Mol. Biol. Res. 1995, 41:11-15.
141. Wee S., Wiederschain D., Maira S.-M., Loo A., Miller C., deBeaumont R., Stegmeier F., Yao Y.-M., Lengauer C. PTEN-deficient cancers depend on PIK3CB. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:13057-13062.
142. Wendel H.-G., De Stanchina E., Fridman J.S., Malina A., Ray S., Kogan S., Cordon-Cardo C., Pelletier J., Lowe S.W. Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy. Nature 2004, 428:332-337.
143. Wendel H.-G., Malina A., Zhao Z., Zender L., Kogan S.C., Cordon-Cardo C., Pelletier J., Lowe S.W. Determinants of sensitivity and resistance to rapamycin-chemotherapy drug combinations in vivo. Cancer Res. 2006, 66:7639-7646.
144. Yap T.A., Sandhu S.K., Carden C.P., De Bono J.S. Poly(ADP-ribose) polymerase (PARP) inhibitors: Exploiting a synthetic lethal strategy in the clinic. CA Cancer J. Clin. 2011, 61:31-49.
145. Young C.D., Nolte E.C., Lewis A., Serkova N.J., Anderson S.M. Activated Akt1 accelerates MMTV-c-ErbB2 mammary tumourigenesis in mice without activation of ErbB3. Breast Cancer Res. 2008, 10:R70.
146. Yu K., Toral-Barza L., Shi C., Zhang W.-G., Lucas J., Shor B., Kim J., Verheijen J., Curran K., Malwitz D.J., Cole D.C., Ellingboe J., Ayral-Kaloustian S., Mansour T.S., Gibbons J.J., Abraham R.T., Nowak P., Zask A. Biochemical, cellular, and in vivo activity of novel ATP-competitive and selective inhibitors of the mammalian target of rapamycin. Cancer Res. 2009, 69:6232-6240.
147. Yuan W., Stawiski E., Janakiraman V., Chan E., Durinck S., Edgar K.A., Kljavin N.M., Rivers C.S., Gnad F., Roose-Girma M., Haverty P.M., Fedorowicz G., Heldens S., Soriano R.H., Zhang Z., Wallin J.J., Johnson L., Merchant M., Modrusan Z., Stern H.M., Seshagiri S. Conditional activation of Pik3ca(H1047R) in a knock-in mouse model promotes mammary tumorigenesis and emergence of mutations. Oncogene 2013, 32:318-326.
148. Zagouri F., Sergentanis T.N., Chrysikos D., Filipits M., Bartsch R. mTOR inhibitors in breast cancer: a systematic review. Gynecol. Oncol 2012, 127:662-672.
149. Zardavas D., Fumagalli D., Loi S. Phosphatidylinositol 3-kinase/AKT/mammalian target of rapamycin pathway inhibition: a breakthrough in the management of luminal (ER+/HER2-) breast cancers?. Curr. Opin. Oncol. 2012, 24:623-634.
150. Zhao L., Vogt P.K. Hot-spot mutations in p110alpha of phosphatidylinositol 3-kinase (pI3K): differential interactions with the regulatory subunit p85 and with RAS. Cell Cycle 2010, 9:596-600.
151. Zhu Y., Zhang X., Liu Y., Zhang S., Liu J., Ma Y., Zhang J. Antitumor effect of the mTOR inhibitor everolimus in combination with trastuzumab on human breast cancer stem cells in vitro and in vivo. Tumour Biol. 2012, 33:1349-1362.